MEDULLARY THYROID CARCINOMA
Clinical trials for MEDULLARY THYROID CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CARCINOMA trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Matched conditions: MEDULLARY THYROID CARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Which dose of vandetanib works best for thyroid cancer?
Disease control CompletedThis study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24…
Matched conditions: MEDULLARY THYROID CARCINOMA
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Matched conditions: MEDULLARY THYROID CARCINOMA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC